TECENTRIQ + bevacizumab: NOW APPROVED in 1L unresectable HCC
THE STRENGTH OF SUPERIOR SURVIVAL
For over a decade, systemic therapy
for 1L HCC has shown poor survival
benefit and decreased patient QoL.
TECENTRIQ + bevacizumab,
the first cancer immunotherapy combination in 1L unresectable HCC is revolutionising the treatment paradigm and bringing new hope to patients.1-4
HCC IS AN AGGRESSIVE CANCER WITH
LIMITED SYSTEMIC TREATMENT OPTIONS5
HCC is the 4th leading cause of cancer deaths worldwide6;
less than half of patients with unresectable HCC are still alive
1 year after diagnosis.7
TECENTRIQ + bevacizumab:
THE FIRST CANCER IMMUNOTHERAPY COMBINATION IN 1L UNRESECTABLE HCC4

THE DEVELOPMENT OF TECENTRIQ IS BASED ON AN
EXTENSIVE CLINICAL PROGRAMME ADDRESSING KEY UNMET
MEDICAL NEEDS ACROSS DIFFERENT TUMOUR TYPES.
TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.1
TECENTRIQ + bevacizumab:
SUPERIOR SURVIVAL AND
ESTABLISHED SAFETY IN 1L UNRESECTABLE HCC
What this means for patients with HCC
INTERNATIONAL VIRTUAL LAUNCH EVENTS OF TECENTRIQ + bevacizumab
Watch the videos of international experts, from across the globe, diving into the groundbreaking data from IMbrave150 phase III trial, with a multidisciplinary approach.
Learn how TECENTRIQ + bevacizumab is being incorporated in clinical practice around the world:
Treating with confidence: managing patients on TECENTRIQ + bevacizumab
Patient Case 2: 80 years old HBV+, hypertensive, fatty liver
Patient Case 4: 70 years old, HCV-related cirrhosis, paroxysmal atrial fibrillation and hypercholesterolemia
Patient Case 1: 65 years old, chronic HBV with no liver cirrhosis
Patient Case 3: 60 years old, history of HCV and liver cirrhosis